There has been widespread debate about the role of ARV therapy in preventing HIV transmission since the publication of the 'Swiss statement' in January 2008. This discussion has intensified with the publication of various epidemiological models that examine the potential impact of early and extensive ARV therapy on HIV transmission.

Prevention trial stops

Men and women infected with HIV taking antiretrovirals reduced the risk of transmitting the virus to their sexual partners by 96% according to findings from a large-scale clinical study. HPTN 052 is the first randomised clinical trial to show that treatment with ARVs can reduce the risk of sexual transmission.

Read more ...

Trick or treat

AFAO invited a group of authors to consider the issue of ARV therapy as prevention with a particular focus on its application to the Australian context. Each of these authors makes an important contribution to this question. The resulting monograph is the first in AFAO's HIV Biomedical Prevention Series.

Download Trick or Treat (PDF, 312 KB, 71pp)

A revolution in HIV prevention?

Following an expert seminar in November 2010, the UK-based NAT has launched a report on HIV 'treatment as prevention' and what this means for the future of HIV prevention strategies. The report draws on the experience of a range of experts currently involved in HIV research, treatment, prevention, care and support.

Download the Report (PDF on NAT website)

Good Participatory Practice guidelines

The UNAIDS Good Participatory Practice guidelines aim to provide systematic guidance on the roles and responsibilities of entities funding and conducting biomedical HIV prevention trials towards participants and their communities. Such entities include investigators, research staff, pharmaceutical industry sponsors, and foundations involved in designing, financing, and executing clinical trials research.

Download the Guidelines (PDF on AVAC website)